Hong Ding

USPTO Granted Patents = 40 (Patent Applications = 19)

CIPO Patents = 13 (Patent Applications = 11)

EPO Patents = 18 (Patent Applications = 22)

Average Co-Inventor Count = 7.7

ph-index = 19

Forward Citations = 1,125(Granted Patents)

Location History:

Naperville, IL (US) (2001)
Darien, IL (US) (1999 - 2002)
Hudson, OH (US) (2009 - 2012)
Lincolnshire, IL (US) (2012 - 2013)
Gurnee, IL (US) (2004 - 2024)

Company Filing History:

17 out of 4,177

Abbott Laboratories Corporation

The Sherwin Williams Company

patents

4. 3 out of 80

The Walter and Eliza Hall Institute of Medical Research

where one patent can have more than one assignee

Years Active: 1999-2024

Loading Chart...

40 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11897864 - Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases (2024-02-13),

2. 9315488 - Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases (2016-04-19),

3. 9303025 - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases (2016-04-05),

4. 9174982 - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases (2015-11-03),

5. 9125913 - Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases (2015-09-08),

6. 9072748 - BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases (2015-07-07),

7. 9045444 - Apoptosis promoters (2015-06-02),

8. 8952157 - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases (2015-02-10),

9. 8853209 - 1-oxyalkyl-2-carboxy-7-nonsubstituted indole derivatives (2014-10-07),

10. 8686136 - Apoptosis promoters (2014-04-01),

11. 8614318 - Apoptosis promoters (2013-12-24),

12. 8586754 - BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases (2013-11-19),

13. 8563735 - Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases (2013-10-22),

14. 8546399 - Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases (2013-10-01),

15. 8426422 - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases (2013-04-23),

Title: Hong Ding: A Visionary Inventor Pushing Boundaries in Invention

Introduction:

Hong Ding, a relentless innovator based in Gurnee, IL (US), is a visionary in the world of inventions. With 32 patents to his name, his dedication to pushing the boundaries of what is possible continues to shape the future of technology.

Latest Patents:

Hong Ding's latest patents include "Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases" and "Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases." These patents disclose compounds that inhibit the activity of anti-apoptotic Bcl-2 proteins, offering new avenues for treating diseases where these proteins are expressed.

Career Highlights:

Having worked in prestigious companies like Abbott Laboratories and AbbVie Inc., Hong Ding has honed his skills and expertise in the field of invention. His contributions have driven advancements in healthcare and technology, making him a key player in the industry.

Collaborations:

Throughout his career, Hong Ding has collaborated with talented individuals like Aaron R Kunzer and Steven Elmore. These partnerships have led to the development of groundbreaking inventions and innovative solutions that have made a significant impact in their respective fields.

Conclusion:

In conclusion, Hong Ding's unwavering commitment to innovation and his pioneering spirit make him a true trailblazer in the world of inventions. His work not only inspires fellow inventors but also enriches the world with transformative technologies that have the potential to change lives for the better.

This text is generated by artificial intelligence and may not be accurate.